|
US3959008A
(en)
|
1974-06-24 |
1976-05-25 |
Cities Service Company |
Carbon black
|
|
AU4169800A
(en)
|
1999-03-05 |
2000-09-21 |
Diacrin, Inc. |
Methods for improving graft acceptance in a recipient by administration of a cytokine profile altering agent
|
|
WO2002097050A2
(en)
*
|
2001-05-31 |
2002-12-05 |
Novartis Ag |
Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
|
|
EP1454138B1
(en)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
|
DE60334303D1
(de)
|
2002-07-03 |
2010-11-04 |
Tasuku Honjo |
Immunpotenzierende zusammensetzungen
|
|
CA2556752C
(en)
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
|
RU2583876C2
(ru)
|
2009-08-17 |
2016-05-10 |
Роше Гликарт Аг |
Иммуноконъюгаты направленного действия
|
|
CN103068405A
(zh)
|
2010-04-15 |
2013-04-24 |
西雅图基因公司 |
靶向吡咯并苯并二氮杂卓结合物
|
|
RU2013139267A
(ru)
|
2011-02-10 |
2015-03-20 |
Рош Гликарт Аг |
Улучшенная иммунотерапия
|
|
CN105440123B
(zh)
|
2011-02-10 |
2020-10-09 |
罗切格利卡特公司 |
突变体白介素-2多肽
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
KR101721301B1
(ko)
|
2011-08-23 |
2017-03-29 |
로슈 글리카트 아게 |
이중특이적 항원 결합 분자
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
PL3434695T3
(pl)
|
2012-08-07 |
2021-05-17 |
Roche Glycart Ag |
Ulepszona immunoterapia
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
US9159294B2
(en)
|
2014-01-31 |
2015-10-13 |
Google Inc. |
Buttonless display activation
|
|
PT3102595T
(pt)
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
EP3104866A4
(en)
*
|
2014-02-14 |
2017-08-02 |
Bellicum Pharmaceuticals, Inc. |
Methods for activating t cells using an inducible chimeric polypeptide
|
|
KR102493543B1
(ko)
|
2014-07-21 |
2023-01-30 |
데리니아, 인크. |
자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
|
|
ES2774380T3
(es)
|
2014-08-29 |
2020-07-20 |
Hoffmann La Roche |
Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano
|
|
US20160362469A1
(en)
*
|
2015-06-12 |
2016-12-15 |
Tianxin Wang |
Methods for protein modification in pharmaceutical applications
|
|
WO2017075537A1
(en)
*
|
2015-10-30 |
2017-05-04 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
WO2017123559A2
(en)
*
|
2016-01-11 |
2017-07-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric proteins and methods of regulating gene expression
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
US10898576B2
(en)
|
2016-03-16 |
2021-01-26 |
Yanhui Xie |
Glucocorticoid combined with polyethylene glycol-modified interleukin 2 for treating respiratory disease
|
|
US10669338B2
(en)
|
2016-06-17 |
2020-06-02 |
Immunomedics, Inc. |
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
KR102379464B1
(ko)
*
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
CA3032430A1
(en)
|
2016-08-16 |
2018-02-22 |
Epimab Biotherapeutics, Inc. |
Monovalent asymmetric tandem fab bispecific antibodies
|
|
US10906957B2
(en)
|
2016-09-27 |
2021-02-02 |
Epicentrx, Inc. |
Immunomodulatory fusion proteins
|
|
CN107915777A
(zh)
|
2016-10-09 |
2018-04-17 |
泰州迈博太科药业有限公司 |
一种重组免疫细胞因子及其应用
|
|
CN107082812B
(zh)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
KR102920712B1
(ko)
|
2017-05-24 |
2026-01-30 |
노파르티스 아게 |
항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
|
|
US20200140547A1
(en)
|
2017-05-26 |
2020-05-07 |
The Johns Hopkins University |
Multifunctional antibody-ligand traps to modulate immune tolerance
|
|
JP2020522495A
(ja)
|
2017-05-30 |
2020-07-30 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物
|
|
AU2018287317B2
(en)
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
|
US20200306301A1
(en)
|
2017-07-03 |
2020-10-01 |
Torque Therapeutics, Inc. |
Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
|
|
IL321812A
(en)
*
|
2017-08-03 |
2025-08-01 |
Synthorx Inc |
Cytokine complexes for the treatment of autoimmune diseases
|
|
US11883503B2
(en)
|
2017-09-25 |
2024-01-30 |
Dingfu Biotarget Co., Ltd. |
Methods and compositions for cancer treatment
|
|
KR20200084880A
(ko)
|
2017-11-06 |
2020-07-13 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
US11970537B2
(en)
|
2017-12-26 |
2024-04-30 |
Nanjing GenScript Biotech Co., Ltd. |
Fusion protein dimer using antibody Fc region as backbone and use thereof
|
|
TW201938196A
(zh)
|
2018-01-18 |
2019-10-01 |
美商南特生物科學股份有限公司 |
融合蛋白擴展
|
|
JP7534215B2
(ja)
|
2018-01-24 |
2024-08-14 |
ベイジン パーカンズ オンコロジー カンパニー リミテッド |
サイトカイン融合タンパク質
|
|
CA3115461A1
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
PE20210313A1
(es)
|
2018-03-28 |
2021-02-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
|
|
MX2020012251A
(es)
*
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
JP2021526026A
(ja)
|
2018-06-08 |
2021-09-30 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
翻訳後修飾が低減したペプチドリンカー
|
|
MX2020014290A
(es)
|
2018-06-22 |
2021-08-05 |
Cugene Inc |
Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
|
|
CN112672753B
(zh)
|
2018-07-09 |
2025-07-08 |
普瑞赛格恩公司 |
融合构建体及其使用方法
|
|
US20200026890A1
(en)
|
2018-07-18 |
2020-01-23 |
Brandon Iglesias |
Smart Equipment Energizer and Method for Using
|
|
WO2020041758A1
(en)
|
2018-08-24 |
2020-02-27 |
City Of Hope |
Masked cytokine conjugates
|
|
CN113286812B
(zh)
|
2018-09-27 |
2025-05-30 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
CA3117853A1
(en)
|
2018-10-29 |
2020-05-07 |
1Globe Biomedical Co., Ltd. |
Novel rationally designed protein compositions
|
|
CN113811549A
(zh)
|
2019-02-21 |
2021-12-17 |
Xencor股份有限公司 |
非靶向和靶向性il-10 fc融合蛋白
|
|
CN114072164A
(zh)
|
2019-03-06 |
2022-02-18 |
德卡生物科学公司 |
Il-10变体分子和治疗炎性疾病和肿瘤的方法
|
|
EP3947449A4
(en)
|
2019-04-01 |
2022-09-07 |
Immetas Therapeutics, Inc. |
BISPECIFIC BINDING MOLECULES THAT TARGET THE TUMORS MICROENVIRONMENT AND AN IMMUNE CHECKPOINT PROTEIN
|
|
CA3136602A1
(en)
|
2019-04-15 |
2020-10-22 |
Qwixel Therapeutics Llc |
Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
AU2020285636A1
(en)
|
2019-05-24 |
2021-11-04 |
Proviva Therapeutics (Hong Kong) Limited |
IL-2 compositions and methods of use thereof
|
|
JP7778571B2
(ja)
|
2019-06-05 |
2025-12-02 |
アッシャー バイオセラピューティクス, インコーポレイテッド |
免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体
|
|
WO2020259536A1
(zh)
|
2019-06-24 |
2020-12-30 |
南京金斯瑞生物科技有限公司 |
单克隆抗体-细胞因子融合蛋白二聚体及其应用
|
|
KR20260089650A
(ko)
|
2019-07-12 |
2026-06-15 |
프로비바 테라퓨틱스 (홍콩) 리미티드 |
Il-2 조성물 및 이의 사용 방법
|
|
AU2020316002B2
(en)
|
2019-07-25 |
2026-05-07 |
The University Of Chicago |
Compositions and methods comprising protease-activated therapeutic agents
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
EP4013775A1
(en)
|
2019-08-12 |
2022-06-22 |
Askgene Pharma, Inc. |
Il-2 fusion proteins that preferentially bind il-2ralpha
|
|
JP2022544405A
(ja)
|
2019-08-15 |
2022-10-18 |
アイジーエム バイオサイエンシズ インコーポレイテッド |
免疫刺激性多量体型結合分子
|
|
EP4017594A1
(en)
|
2019-08-21 |
2022-06-29 |
Askgene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
WO2021062406A1
(en)
|
2019-09-28 |
2021-04-01 |
AskGene Pharma, Inc. |
Cytokine prodrugs and dual-prodrugs
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
BR112022010425A2
(pt)
|
2019-12-03 |
2022-08-23 |
Evotec Int Gmbh |
Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b
|
|
US11648296B2
(en)
|
2019-12-13 |
2023-05-16 |
Synthekine, Inc. |
IL-2 orthologs and methods of use
|
|
AU2021205981A1
(en)
|
2020-01-11 |
2022-07-14 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
|
WO2021158938A1
(en)
|
2020-02-06 |
2021-08-12 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
CN115698063A
(zh)
|
2020-03-06 |
2023-02-03 |
匹兹堡大学联邦高等教育系统 |
血清白蛋白结合纳米抗体组合物以及其使用方法
|
|
US20230181712A1
(en)
|
2020-05-11 |
2023-06-15 |
Hoffmann-La Roche Inc. |
Combination therapy with modified pbmcs and an immunoconjugate
|
|
KR20230010251A
(ko)
|
2020-05-13 |
2023-01-18 |
보넘 테라퓨틱스, 인크. |
단백질 복합체의 조성물 및 그의 사용 방법
|
|
CA3178657A1
(en)
|
2020-05-19 |
2021-11-25 |
William Winston |
Activatable il-12 polypeptides and methods of use thereof
|
|
EP4178530A1
(en)
|
2020-07-09 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Concentrated compositions of proteins, their preparation and use thereof
|
|
US11028174B1
(en)
|
2020-07-28 |
2021-06-08 |
Lepu Biopharma Co., Ltd. |
Bifunctional molecules targeting PD-L1 and TGF-β
|
|
US20230416364A1
(en)
|
2020-08-13 |
2023-12-28 |
Bristol-Myers Squibb Company |
Methods of redirecting of il-2 to target cells of interest
|
|
US11865082B2
(en)
|
2020-09-09 |
2024-01-09 |
Hoffmann-La Roche Inc. |
Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
|
|
KR20230112632A
(ko)
|
2020-10-23 |
2023-07-27 |
애셔 바이오테라퓨틱스, 인크. |
면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
|
|
KR20230117122A
(ko)
|
2020-12-04 |
2023-08-07 |
에프. 호프만-라 로슈 아게 |
pH 의존성 돌연변이체 인터류킨-2 폴리펩티드
|
|
WO2022125694A1
(en)
|
2020-12-09 |
2022-06-16 |
Asher Biotherapeutics, Inc. |
Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
|
|
JP2023553216A
(ja)
|
2020-12-09 |
2023-12-20 |
アシャ バイオセラピューティクス,インク. |
遺伝子操作細胞療法のための標的化サイトカイン構築物
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
WO2022150791A2
(en)
|
2021-01-11 |
2022-07-14 |
Synthekine, Inc. |
Compositions and methods related to il2 receptor binding
|
|
US20250051413A1
(en)
|
2021-01-12 |
2025-02-13 |
Askgene Pharma Inc. |
Chimeric molecules comprising il-12 agonist polypeptide
|
|
US20240076355A1
(en)
|
2021-01-14 |
2024-03-07 |
AskGene Pharma, Inc. |
Interferon Prodrugs and Methods of Making and Using the Same
|
|
EP4284819A1
(en)
|
2021-02-01 |
2023-12-06 |
Askgene Pharma, Inc. |
Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide
|
|
TW202302148A
(zh)
|
2021-02-12 |
2023-01-16 |
美商欣爍克斯公司 |
使用il-2接合物和抗pd-1抗體或其抗原結合片段的肺癌組合療法
|
|
AU2022231874A1
(en)
|
2021-03-09 |
2023-07-27 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
|
|
CN117015555A
(zh)
|
2021-03-09 |
2023-11-07 |
豪夫迈·罗氏有限公司 |
Pd-1靶向il-2变体免疫缀合物和抗tyrp1/抗cd3双特异性抗体的组合疗法
|
|
WO2022262496A1
(en)
|
2021-06-17 |
2022-12-22 |
Suzhou Fuse Biosciences Limited |
Immunoconjugate molecules and related methods and compositions thereof
|
|
BR112023026660A2
(pt)
|
2021-06-24 |
2024-03-05 |
Bristol Myers Squibb Co |
Armadilhas do ligante fator de crescimento transformante-beta para o tratamento de doença
|
|
AU2022307460A1
(en)
|
2021-07-09 |
2024-01-04 |
Bright Peak Therapeutics Ag |
Checkpoint inhibitors conjugated to il-2, and uses thereof
|
|
WO2023281482A1
(en)
|
2021-07-09 |
2023-01-12 |
Bright Peak Therapeutics Ag |
Cd20-targeted il-2 and its uses
|
|
US20230201364A1
(en)
|
2021-07-09 |
2023-06-29 |
Bright Peak Therapeutics Ag |
Antibody conjugates and manufacture thereof
|
|
KR20240034221A
(ko)
|
2021-07-09 |
2024-03-13 |
브라이트 피크 테라퓨틱스 아게 |
염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
|
|
AU2022306788A1
(en)
|
2021-07-09 |
2024-01-04 |
Bright Peak Therapeutics Ag |
Conjugates of checkpoint inhibitors with il-2, and uses thereof
|
|
CA3228964A1
(en)
|
2021-08-17 |
2023-02-23 |
William Winston |
Inducible cytokine prodrug and pd-1/pd-l1 combination therapy
|
|
EP4387987A2
(en)
|
2021-08-18 |
2024-06-26 |
Werewolf Therapeutics, Inc. |
Activatable inteferon polypeptides and methods of use thereof
|
|
US20240390506A1
(en)
|
2021-09-28 |
2024-11-28 |
Suzhou Fuse Biosciences Limited |
Immunoconjugates containing tnf-alpha and related methods and compositions thereof
|
|
EP4429706A1
(en)
|
2021-10-14 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
IL312221A
(en)
|
2021-10-20 |
2024-06-01 |
Synthekine Inc |
Heterodimeric fc cytokines and uses thereof
|
|
WO2023102493A2
(en)
|
2021-12-01 |
2023-06-08 |
Synthekine, Inc. |
Il10 variants and uses thereof
|
|
EP4452327A1
(en)
|
2021-12-20 |
2024-10-30 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|